Internal Program
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About BenevolentAI
BenevolentAI's mission is to transform drug discovery by applying advanced artificial intelligence and machine learning to vast biomedical datasets. Its key achievement is the development of a proprietary, decade-invested knowledge graph and AI platform that generates novel, testable hypotheses for target identification and patient stratification. The company's strategy is dual-pronged: advancing an internal pipeline of drug candidates while securing strategic collaborations with large pharma to validate its platform and generate revenue. It became a publicly traded company on Euronext Amsterdam in 2022.
View full company profileAbout BenevolentAI
BenevolentAI's mission is to transform drug discovery by applying advanced artificial intelligence and machine learning to vast biomedical datasets. Its key achievement is the development of a proprietary, decade-invested knowledge graph and AI platform that generates novel, testable hypotheses for target identification and patient stratification. The company's strategy is dual-pronged: advancing an internal pipeline of drug candidates while securing strategic collaborations with large pharma to validate its platform and generate revenue. It became a publicly traded company on Euronext Amsterdam in 2022.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |
| NP001 | Neuvivo | Phase 3 |